empagliflozin, linagliptin, and metformin

Action and Spectrum

Drug Interaction

Adverse Reaction

1-10%: 

Diarrhea 

Gastroenteritis 

Urinary tract infection 

Headache 

Nasopharyngitis 

Constipation 

<1%: 

Hypoglycemia 

Frequency undefined: 

Lactic acidosis 

Black Box Warning

Contraindication / Caution

empagliflozin, linagliptin, and metformin are contraindicated in patients hypersensitive to the active ingredient. 

Pregnancy / Lactation

Pregnancy consideration:  

The drug is not indicated during the second and third trimesters of pregnancy. 

Breastfeeding warnings:  

Metformin is excreted in breast milk. 

The presence of linagliptin and empagliflozin in breastmilk is unknown 

Pregnancy category: 

• Category A: well-controlled and Satisfactory studies do not show risk to the fetus in the first/later trimester.        
• Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women        
• Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.       
• Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.        
• Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.        
• Category N: There is no data available for the drug under this category 

Pharmacology

Adminstartion

Patient Information Leaflet

Patient information leaflet 

Generic Name: empagliflozin, linagliptin, and metformin 

Pronounced: em-pag-lif-loz-in, lina-glip-tin, and met-for-min 

Why do we use empagliflozin, linagliptin, and metformin? 

Empagliflozin, linagliptin, and metformin belong to the category of Antidiabetic Agents. It helps to treat diabetes mellitus type 2.